Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

CORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD

Enlicitide has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C), among other contributing factors, in patients with 

, according to data from the CORALreef AddOn clinical trial.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by Alberico Catapano, PhD, research director and head of the laboratory of lipoproteins and atherosclerosis and of the lipid clinic at MultiMedica IRCCS.

“As a clinician who takes care of patients with ASCVD or at risk for ASCVD, I’m really excited to see a pill that, when added to statin therapy, can lower LDL cholesterol by 60% or more,” Ann Marie Navar, MD, PhD, associate professor, department of internal medicine, UT Southwestern Medical Center and an investigator in the trial, told 

 in an exclusive interview. “When we think about guidelines recommending targets of <55 for our highest-risk patients, it’s going to take more than statins to get most of our patients to those goals. I’m excited to have an oral option.”

CORALreef AddOn was a phase 3, randomized, double-blind study evaluating the safety and efficacy of enlicitide compared to ezetimibe, bempedoic acid, or a combination in adults with hypercholesterolemia. Patients were eligible if they presented with a history of major 

atherosclerotic cardiovascular disease (ASCVD)

 event, were currently undergoing treatment with a low, moderate, or high intensity statin, or were on a stable dose of all background lipid-lowering therapies (LLTs) with no planned changes during the study, among other criteria. Patients with homozygous or heterozygous familial hypercholesterolemia or NYHA class IV 

Patients enrolled in the study were randomly assigned to either the treatment arm, consisting of enlicitide 20mg, ezetimibe-matching placebo, and bempedoic acid-matching placebo once daily orally for roughly 56 days, or 1 of 3 active comparators, including ezetimibe 10mg, bempedoic acid 180mg, or ezetimibe and bempedoic acid. The primary outcome was mean percent change from baseline in LDL-C at day 56; secondary outcomes included mean percent change in apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), and lipoprotein(a), among others.

Ultimately, 301 patients were enrolled in the study – of these, 101 were assigned to the treatment arm, 50 were assigned to both the ezetimibe and bempedoic acid arms, and 100 were assigned to the group receiving both comparators. Catapano and colleagues recorded a mean age of 64 years among the patients. All had hypercholesterolemia with either a history of a major ASCVD event or were at high risk. Fasting lipids were obtained at screening and on days 1, 21, and 56 and at treatment discontinuation.

Catapano and colleagues noted a 65% reduction in LDL-C with enlicitide versus 6% with bempedoic acid, 28% with ezetimibe, and 37% with the combination. These results were similar across all included subgroups. Additionally, patients receiving enlicitide had a substantially greater reduction in ApoB and non-HDL-C than any comparator group. Adverse events and discontinuations, totaling 2-4%, were also similar across all groups.

Catapano, Navar, and colleagues determined that enlicitide is superior to ezetimibe, bempedoic acid, and a combination of both. These results, on top of those from the previously concluded CORALreef Lipids and CORALreef HeFH trials, emphasize the overall efficacy of the investigative PCSK9 inhibitor. Moving forward, Navar highlights the ongoing CORALreef Outcomes trial, the results of which will reportedly influence the potential submission of a New Drug Application.

Editors’ Note: Navar reports disclosures with Esperion Therapeutics, Bristol Myers Squibb, Amgen, Janssen Pharmaceuticals, Eli Lilly, Novo Nordisk, and others.

Catapano A, Mikhailova E, Navar A, et al. Efficacy and Safety of Enlicitide Decanoate, an Oral Macrocyclic Peptide Inhibitor of PCSK9, Compared With Bempedoic Acid, Ezetimibe, or Bempedoic Acid Co-administered With Ezetimibe in Statin-treated Adults With Hypercholesterolemia: Phase 3 CORALreef AddOn Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

Merck Sharp & Dohme LLC. A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn). ClinicalTrials.gov Identifier: NCT06450366. Updated March 27, 2026. Accessed April 7, 2026. 

https://clinicaltrials.gov/study/NCT06450366

Videos

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The first quarter of 2026 delivered a series of regulatory milestones, guideline updates, and late-phase clinical data that reshaped key areas across 

 and immunology. US Food & Drug Administration (FDA) approvals expanded treatment options for pediatric hereditary angioedema (HAE) and allergic fungal rhinosinusitis. Label changes also expanded treatment options for 

At the same time, new international guidance sought to standardize epinephrine use and prioritize rapid access to on-demand HAE therapies. Pipeline progress, including phase 3 food allergy immunotherapy, reflected continued movement toward precision-driven care. This review spotlights 9 allergy headlines in Q1 of 2026.

FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years with Prior Surgery

The FDA approved dupilumab (Dupixent) for allergic fungal rhinosinusitis (AFRS) in adults and pediatric patients aged ≥ 6 years with prior sinonasal surgery, marking the first therapy specifically indicated for the condition. The decision addressed a disease characterized by type 2 inflammation and high postsurgical recurrence rates.

Clinical trial data demonstrated reductions in signs and symptoms, with improvements in nasal congestion, polyp burden, and need for corticosteroids or repeat surgery, supporting the biologic’s role in disease modification.

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

The FDA approved BioCryst’s oral berotralstat (ORLADEYO) for long-term prophylaxis of HAE in children aged 2–11 years, becoming the first once-daily oral preventive option in this population.

Prior pediatric prophylaxis relied on injectable therapies, which were associated with caregiver burden and adherence challenges. Investigators highlighted that the oral formulation may reduce treatment barriers and improve the quality of life for pediatric patients and families.

FDA Removes Age Requirement for Epinephrine Nasal Spray, Now Based on Weight Alone

The FDA removed the minimum age requirement for epinephrine nasal spray (neffy), shifting to weight-based eligibility alone. This labeling change expanded access to needle-free epinephrine for younger children at risk for anaphylaxis. The update also included real-world usability considerations such as storage flexibility and administration guidance.

FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic Reactions

The FDA issued a complete response letter for dibutepinephrine (Anaphylm) sublingual film for type I allergic reactions. The agency cited deficiencies in human factors validation, including difficulty opening packaging and improper placement, which raised safety concerns during anaphylaxis treatment.

Pediatric HAE Guideline Recommends Sebetralstat as First-Line Therapy

A new international pediatric HAE guideline recommended oral sebetralstat as a first-line acute treatment option for adolescents aged ≥12 years. The guidance emphasized early administration and availability of on-demand therapy to reduce attack severity and duration.

Recommendations also stressed maintaining access to treatment for ≥ 2 attacks and ensuring education for patients and caregivers to support timely intervention.

Updated Anaphylaxis Guidelines, Early Management Priorities

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

An international expert panel led by Timothy E. Dribin, MD, from Cincinnati Children’s Hospital Medical Center, released consensus-based recommendations to reduce variation in epinephrine use during allergic reactions. The guidance emphasized epinephrine for multi-organ involvement or severe respiratory or cardiovascular symptoms, while acknowledging uncertainty in moderate isolated cutaneous presentations.Experts noted persistent underuse of epinephrine, with real-world data showing only a minority of patients receive it prior to emergency department arrival, underscoring the need for clearer action plans.

FDA Accepts NDA for Bezuclastinib in Non-Advanced Systemic Mastocytosis

The FDA accepted a new drug application (NDA) for Cogent Biosciences’ bezuclastinib in non-advanced systemic mastocytosis, supported by clinical trial data evaluating symptom improvement and disease burden reduction. The FDA assigned a PDUFA target action date of December 30, 2026.

FDA Grants Fast Track Designation to BW-20805 siRNA Therapy for HAE

The FDA granted Fast Track designation to Argo Biopharmaceutical’s BW-20805, an investigational siRNA therapy targeting the kallikrein pathway for HAE prophylaxis. The designation reflects potential for sustained disease suppression and long-acting prevention strategies.

VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD

Phase 3 VITESSE trial data demonstrated strong desensitization outcomes with the VIASKIN peanut patch, an epicutaneous immunotherapy, in peanut-allergic children. The study showed that 82.8% of children receiving the peanut patch vs 48% receiving placebo increased their eliciting dose over 12 months.

Articles

Q1 2026 brought multiple allergy/immunology inflection points: dupilumab became the first indicated therapy for allergic fungal rhinosinusitis in post-surgical patients ≥6 years, and oral berotralstat enabled once-daily HAE prophylaxis in children 2–11. Epinephrine access broadened as neffy moved to weight-only labeling, while dibutepinephrine sublingual film drew an FDA CRL over human-factors risks. International guidance prioritized early epinephrine in severe reactions and first-line oral sebetralstat for adolescent HAE attacks. Pipeline advances included bezuclastinib’s NDA, Fast Track siRNA prophylaxis, and positive VIASKIN phase 3 data.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Food Allergy

Q1 2026 Recap: Allergy News and Updates

Jawad Butt, MD, PhD, is a research fellow in the department of cardiology at Copenhagen University Hospital and the University of Glasgow.

Finerenone Efficacy in HF Unchanged by Ischemic Heart Disease, With Jawad Butt, MD, PhD

heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF)

, finerenone’s beneficial effects were consistent regardless of ischemic heart disease (IHD) status, according to a prespecified analysis of the FINEARTS-HF trial.

 in New Orleans, Louisiana, by Jawad Butt, MD, PhD, a research fellow in the department of cardiology at Copenhagen University Hospital and the University of Glasgow.

“For clinicians, we know that the management of heart failure with a mildly reduced or preserved ejection fraction is complex,” Butt told 

 in an exclusive interview. “We know that ischemic heart disease is prevalent – we meet these patients in our everyday clinic. So the main take-home message for clinicians is that this treatment makes clinical decision-making so much easier, since we don’t have to differentiate between patients who do and do not have a history of IHD.”

FINEARTS-HF was a randomized, double-blind, placebo-controlled trial incorporating patients with symptomatic HF. Eligible patients were ≥40 years with New York Heart Association (NYHA) class II-IV HF, left ventricular ejection fraction (LVEF) ≥40%, or n-terminal prohormone B-type natriuretic peptide (NT-proBNP) ≥300 pg/mL in sinus rhythm, among other criteria. Patients were excluded if they exhibited an estimated glomerular filtration rate (eGFR) <25 mL/min/1.73m2 at screening or randomization, serum/plasma potassium >5 mmol/L at screening or randomization, or myocardial infarction, among other criteria.

The study included a primary outcome of a composite of total worsening HF events, which were defined as first or recurrent unplanned hospitalization or urgent visit for HF and death from cardiovascular causes. The individual components were also assessed. The trial included a median follow-up period of 32 months.

During the study, 3003 patients were randomized to receive finerenone, while 2998 were randomized to placebo. After the follow-up period, 1083 primary outcome events occurred in 624 patients in the treatment arm, and 1283 occurred among 719 patients in the placebo arm. The trial ultimately determined that finerenone reduced total worsening HF event rates and death from cardiovascular causes in these patients.

The present secondary analysis included all 6001 patients, of whom 3236 had a history of IHD. After comparing these patients to those without IHD, Butt and colleagues noted a significantly higher risk of the primary outcome among those with IHD (risk ratio [RR], 1.54; 95% CI, 1.33-1.79), as well as each of the endpoint’s components (total HF events: RR, 1.54; 95% CI, 1.03-1.82; CV death: HR, 1.58; 95% CI, 1.29-1.94; all-cause death; HR, 1.34; 95% CI, 1.16-1.55), even after adjustment for known prognostic variables.

However, the beneficial effect of finerenone on this primary outcome did not differ based on the presence of IHD (no IHD: RR, 0.81; 95% CI, 0.67-0.99; IHD: RR, 0.86; 95% CI, 0.73-1.01; 

 interaction = 0.68). Consistent effects were observed for all components of the primary outcome and all-cause death. Ultimately, Butt and colleagues determined that a history of IHD had no significant bearing on finerenone’s effects in HFmrEF/HFpEF.

“Historically, we haven’t had many effective treatments in patients with HFmrEF/HFpEF, until SGLT2 inhibitors were approved some years ago,” Butt said. “Last year, the FDA approved finerenone for the treatment and management of these patients. Now that we have done several analyses, including looking at the efficacy and safety of finerenone on top of SGLT2 inhibitors, I definitely think this will get a place in international guidelines for the management of HFmrEF/HFpEF.”

Editors’ Note: Butt reports disclosures with AstraZeneca, Bayer, and Novartis.

Butt J, Jhund P, Henderson A, et al. Ischemic Heart Disease Does Not Modify the Beneficial Effects of Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of the FINEARTS-HF Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

Bayer. Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF). ClinicalTrials.gov Identifier: NCT04435626. Updated August 26, 2025. Accessed April 7, 2026. 

https://clinicaltrials.gov/study/NCT04435626

Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. 

Butt discusses his secondary analysis of the FINEARTS-HF trial, which demonstrated consistent treatment efficacy in patients with and without a history of IHD.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March brought a series of meaningful developments in hepatology, spanning regulatory milestones, emerging therapies, and evolving perspectives on liver disease risk and management. From the first approved treatment for cholestatic pruritus in primary biliary cholangitis (PBC) to ongoing efforts to improve viral hepatitis care, the month highlighted both progress and persistent challenges across the field.

A major highlight came with the US Food and Drug Administration (FDA) approval of linerixibat, marking the first US-approved therapy specifically for cholestatic pruritus in PBC and signaling a shift toward more targeted management of symptom burden in cholestatic liver diseases. At the same time, growing attention to hepatitis B and D underscored the need for expanded treatment strategies and continued innovation, with new discussions around care delivery and promising investigational therapies like brelovitug.

The month also emphasized the importance of broader clinical context, from emerging research on intergenerational drivers of MASLD to novel insights into diet’s role in hepatocellular carcinoma risk. Alongside these advances, increasing focus on pruritus across rare liver diseases reflects a broader push to address quality-of-life impacts that have long been underrecognized.

Here’s a look at 6 key hepatology headlines from March 2026 you may have missed:

FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC

On March 19, 2026, the FDA approved GSK’s linerixibat (Lynavoy) for the treatment of cholestatic pruritus in adult patients with PBC, making it the first medicine approved in the US for this indication. The decision was based on data from the global phase 3 GLISTEN trial, which met both primary and key secondary endpoints, demonstrating significant, rapid and sustained improvements in cholestatic pruritus and itch-related sleep interference versus placebo.

Liver Lineup: Breaking Down Barriers in Hepatitis B Management

On the latest episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, welcome guest Su Wang, MD, MPH, to discuss the current landscape of hepatitis B care and evolving guidelines. The trio reviews the changing management of hepatitis B and explores how to move care beyond silos with expanded treatment and provider empowerment.

Inside the AZURE Program of Brelovitug for Hepatitis D, With Tatyana Kushner, MD

For clinicians managing hepatitis D virus (HDV) infection, the stakes are uniquely high. Unlike many other chronic viral hepatitides, HDV is widely recognized as the most aggressive form of viral hepatitis, often leading to rapid disease progression and severe long-term complications. Tatyana Kushner, MD, discusses brelovitug’s potential for the treatment of HDV and what will be learned from the phase 3 AZURE program.

New Hope for Hepatitis D? Brelovitug and the AZURE Program

Understanding Intergenerational Risk Factors for MASLD, With Stefani Tica, MD, MPH

As rates of metabolic dysfunction-associated steatotic liver disease (MASLD) continue to rise, experts are increasingly examining how risk for metabolic disease may develop earlier in life than previously recognized, with emerging evidence suggesting that factors shaping MASLD risk may extend beyond an individual’s current metabolic health to include early-life exposures and parental health. Stefani Tica, MD, MPH, recaps her research suggesting MASLD risk may develop early in life, highlighting the impact of parental factors and cumulative childhood adiposity.

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD

For patients with rare cholestatic liver diseases, pruritus is a debilitating, often underrecognized symptom that can severely disrupt sleep, daily function, and quality of life. Frequently worsening at night and with heat or activity, it remains difficult to measure and does not reliably correlate with standard biomarkers like bile acids or bilirubin. As awareness grows and new therapies are being studied, there is increasing urgency to better recognize and more effectively treat this overlooked but life-altering burden. Mercedes Martinez, MD, highlights both the clinical burden of cholestatic pruritus and the growing promise of targeted therapies like maralixibat.

When Does MASLD Risk Begin? New Research on Early-Life Factors

Dietary Protein as a Modifiable Risk Factor in Liver Cancer, With Wei-Xing Zong, PhD

In a recent study published in Science Advances, investigators from Rutgers University linked dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management. Wei-Xing Zong, PhD, provides additional insight into his team’s research and the clinical significance of their findings.

Key hepatology updates from March 2026, including a first-in-class PBC therapy, viral hepatitis insights, and emerging research in MASLD and HCC.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

6 Hepatology Headlines You Missed in March 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

The month of March 2026 highlighted a variety of key news headlines within the dermatology space, including many resulting from the 

2026 American Academy of Dermatology (AAD) Annual Meeting

In March, the dermatology world delivered a mix of head-to-head shakeups, long-term data, and meaningful 

-related developments across the inflammatory skin disease landscape. In psoriasis, new findings are raising fresh questions about how best to sequence therapies, as risankizumab goes head-to-head with deucravacitinib, and emerging oral medications such as zasocitinib and icotrokinra continue to build momentum.

New findings in atopic dermatitis are also adding to an increasingly competitive biologic landscape. From shifting hierarchies for treatment to expanding therapeutic agents, this iteration of 

’s ‘Month in Review’ series hints at where dermatologic care may be headed next:

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial

In data highlighted at AAD 2026, risankizumab (Skyrizi) therapy demonstrated significantly greater clearance of patients’ skin than deucravacitinib (Sotyktu) at the 16-week mark across a broad range of subgroups in adults with biologic-naïve moderate plaque psoriasis. These findings, resulting from a subgroup analysis of the phase 4 IMMpactful trial, help to extend the primary efficacy findings of IMMpactful which were first released at the Fall Clinical Dermatology Conference in October 2025.

Sustained PASI Responses Observed Through Week 60 with Zasocitinib, With Melinda Gooderham, MD

In other late-breaking data released during AAD, phase 3 findings suggest zasocitinib may be reshaping the oral medication landscape for moderate-to-severe plaque psoriasis, with investigators noting high levels of skin clearance known to usually be the domain of biologics. These findings were addressed by investigator Melinda Gooderham, MD, medical director of the SKiN Centre for Dermatology in Ontario, Canada, who walked through the data resulting from the pivotal phase 3 LATITUDE trial program (NCT06671483).

RADIANT-AD: Rademikibart Effective Over 52 Weeks in Atopic Dermatitis, With Cheng Zhou, MD

Rademikibart in adults and adolescents living with moderate-to-severe atopic dermatitis was also highlighted at AAD in late-breaking data sessions, with findings suggesting the drug’s use leads to rapid and clinically significant improvements sustained through 52 weeks. The phase 3 RADIANT‑AD trial demonstrated rapid, clinically meaningful improvements in adults and adolescents by Week 16 across all major efficacy endpoints. By 1 year of use, a large majority of those on rademikibart attained near‑maximal skin clearance and sustained pruritus control.

ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

These findings highlight 1-year data from the phase 3 ICONIC-LEAD trial, confirming icotrokinra (ICOTYDE) as delivering durable clearance of skin as well as meaningful patient-reported improvements among adult and adolescent patients living with moderate-to-severe plaque psoriasis. There were also no new safety signals through Week 52. The results in adolescent patients, presented across 2 companion posters at AAD, were especially significant given the lack of approved advanced oral options for this population. The data were highlighted by Jennifer Soung, MD, founder and director of Clinical Research at Southern California Dermatology in Santa Ana, California.

Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis

In 1 notable FDA decision from March 2026, the agency approved icotrokinra (ICOTYDE) for patients with moderate to severe plaque psoriasis aged 12 years and older weighing at least 40 kg. Those eligible for the drug must also be candidates for systemic therapy or phototherapy. Johnson & Johnson announced the FDA’s decision on March 18, 2026, marking a first for an oral targeted peptide designed to selectively block the interleukin (IL)-23 receptor. The move introduced a new mechanistic class to the psoriasis treatment landscape following the phase 3 ICONIC program

FDA Approves Secukinumab for Pediatric Patients 12 Years and Older with HS

Another FDA approval from March 2026 was for secukinumab in moderate to severe hidradenitis suppurativa (HS). The drug was approved by the agency for pediatric patients aged 12 and older, making it the only IL-17A inhibitor currently indicated for this population. Secukinumab is a fully human monoclonal antibody formulated to directly target IL-17A, a key cytokine driving the inflammatory pathways implicated in several immune-mediated conditions. This approval of the drug provides a differentiated biologic option to an area where options for younger patients with HS have often been limited.

March 2026 brought pivotal dermatology updates spanning competitive head-to-head psoriasis data, maturing durability readouts for emerging oral agents, and consequential FDA approvals. Risankizumab showed superior week-16 clearance versus deucravacitinib in biologic-naïve moderate plaque psoriasis across multiple subgroups, sharpening therapy-sequencing debates. Zasocitinib delivered sustained high-level clearance through week 60, while icotrokinra demonstrated durable week-52 efficacy with meaningful PRO gains, including notable adolescent outcomes. In atopic dermatitis, rademikibart produced rapid improvements maintained through 52 weeks with strong pruritus control.

This summary of March 2026 highlights key news and developments in the dermatology news space.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

6 Dermatology Headlines You Missed in March 2026

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia Risk Signals in Late-Onset Depression, With Lingfeng Xue, PhD 

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: The G7 15-Day System and CGM Innovations at Dexcom, With Jessica Castle, MD

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

5 Gastroenterology Headlines You Missed in March 2026

John Cijan He, MD, PhD, is a Professor of Medicine and Pharmacological Sciences and Chief of the Division of Nephrology at the Icahn School of Medicine at Mount Sinai.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

6 Psychiatry Headlines You Missed in March 2026 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.

Cardiomyopathy

Arrhythmia

ACC.26 Recap: 6 Practice-Changing Trials to Know

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

FDA News

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Q1 2026 Recap: Top FDA Approvals

Catch up on the hematology headlines you missed in March 2026. 

Hematology

4 Hematology Headlines You Missed In March 2026

Amgen has announced positive topline results from their phase 3 trial comparing teprotumumab-trbw – administered via an on-body injector – to placebo.

News Report

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Thyroid Disorders

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Jane M. Grant-Kels, MD, is the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

This Q&A interview at AAD 2026 highlights health information technologies and AI tools used in dermatology practices.

Latest News

CORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD

Q1 2026 Recap: Allergy News and Updates

Finerenone Efficacy in HF Unchanged by Ischemic Heart Disease, With Jawad Butt, MD, PhD

6 Hepatology Headlines You Missed in March 2026

6 Dermatology Headlines You Missed in March 2026